Current Report Filing (8-k)
February 21 2018 - 3:43PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 15,
2018
Wound Management Technologies, Inc.
(Exact name of registrant as specified in its charter)
Texas
|
000-11808
|
59-2219994
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
1200 Summit Avenue, Suite 414
Fort Worth, Texas
|
76102
|
(Address of principal
executive offices)
|
(zip code)
|
Registrant’s telephone number, including area code: (817)
-529-2300
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check
mark whether the registrant
is an
emerging growth company as defined in in Rule 405 of
the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of
this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Effective
as of February 20, 2018, the Company has appointed J. Michael
Carmena, 62, to serve as the Company’s new Chief Executive
Officer. Mr. Carmena has served as the Company’s Chief
Financial Officer since 2016.
Prior
to joining the Company, Mr. Carmena served as Senior Director,
Business & Sales Operations, of Smith and Nephew plc, formerly
known as Healthpoint Biotherapeutics. Mr. Carmena previously served
Healthpoint Biotherapeutics as Senior Director, Finance &
Administration (from 2008 to 2010) and as Controller (from 1998 to
2008). Mr. Carmena began his career at Arthur Andersen & Co.,
after graduating, magna cum laude, with a BBA in Accounting from
Texas Christian University in 1978.
The
Board of Directors of the Company believes that Mr. Carmena’s
leadership skills are well-suited to maintaining the
Company’s current trajectory.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Wound Management Technologies, Inc.
|
|
|
|
|
|
Date:
February 20, 2018
|
By:
|
/s/
Michael Carmena
|
|
|
Name:
|
Michael Carmena
|
|
|
Title:
|
Chief Executive
Officer
|
|